Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Sarepta Therapeutics
Sarepta Therapeutics
Sarepta cites 'overburdened' FDA as factor in DMD gene therapy delay
Fierce Biotech
Fri, 09/11/20 - 10:55 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
Sarepta shares fall on potential regulatory delay for experimental Duchenne drug
Marketwatch
Thu, 09/10/20 - 10:21 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
Sarepta Therapeutics Gets Fast-Track FDA Review For Muscular Dystrophy Drug
Investors Business Daily
Tue, 08/25/20 - 10:00 pm
Sarepta Therapeutics
FDA
fast track
Duchenne Muscular Dystrophy
casimersen
Sarepta bags drug to fully unlock DMD gene therapy opportunity
Fierce Biotech
Thu, 07/2/20 - 11:19 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Hansa Biopharma
gene therapy
Sarepta expands gene therapy toolkit, bets $72.5M to hitch a ride on Codiak's exosome tech
Endpoints
Mon, 06/22/20 - 10:26 am
Sarepta Therapeutics
Codiak Biosciences
gene therapy
Sarepta, with new data, plans final push for limb-girdle gene therapy
BioPharma Dive
Mon, 06/8/20 - 10:42 am
Sarepta Therapeutics
Limb Girdle Muscular Dystrophy
gene therapy
SRPT-9003
FDA Flags Risk of Infection, Kidney Damage for Sarepta Duchenne Drugs
Xconomy
Wed, 01/22/20 - 06:41 pm
Sarepta Therapeutics
Vyondys 53
Duchenne Muscular Dystrophy
FDA
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Xconomy
Tue, 12/24/19 - 12:00 am
Roche
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
SRP-9001
Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles
Fierce Pharma
Thu, 12/19/19 - 01:11 pm
gene therapy
reimbursement
drug manufacturing
Bristol-Myers Squibb
Pfizer
Biomarin
Sarepta Therapeutics
Gilead Sciences
CAR-T
In stunning twist, FDA approves Sarepta's Duchenne drug it rejected
Biopharma Dive
Fri, 12/13/19 - 12:28 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Vyondys 53
Wave faces key test in bid to challenge Sarepta in DMD
Biopharma Dive
Sat, 11/30/19 - 11:18 pm
Wave Life Sciences
Sarepta Therapeutics
Exondys 51
Duchenne Muscular Dystrophy
Sarepta pays StrideBio $48M for preclinical gene therapies
Fierce Biotech
Fri, 11/15/19 - 11:09 am
Sarepta Therapeutics
StrideBio
gene therapies
CNS
Why Sarepta Therapeutics' Q3 Was Better Than Expected
Motley Fool
Fri, 11/8/19 - 10:35 am
Sarepta Therapeutics
earnings
Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug
Stat
Thu, 11/7/19 - 10:58 pm
Sarepta Therapeutics
Doug Ingram
FDA
Vyondys 53
Duchenne Muscular Dystrophy
Sarepta, in shadow of FDA setback, marks gene therapy progress
BioPharma Dive
Fri, 10/4/19 - 12:36 pm
Sarepta Therapeutics
SRP-9003
limb-girdle muscular dystrophy
muscular dystrophy
gene therapy
Sarepta competitor files with FDA for Duchenne drug
Seeking Alpha
Wed, 10/2/19 - 12:12 pm
Sarepta Therapeutics
NS Pharma
golodirsen
FDA
Duchenne Muscular Dystrophy
Wave takes a different tack from Sarepta in Duchenne
EP Vantage
Thu, 09/12/19 - 10:33 am
Wave Life Sciences
Duchenne Muscular Dystrophy
suvodirsen
Sarepta Therapeutics
The FDA and Sarepta: a window into the real world of drug regulation
Stat
Tue, 09/3/19 - 04:42 pm
FDA
regulatory
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Exondys 51
Vyondys 53
Sarepta now needs flawless progress for gene therapy
Biopharma Dive
Tue, 08/20/19 - 10:58 pm
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
Vyondys 53
gene therapy
SRP-9001
Sarepta Duchenne drug rejected by FDA in surprise decision
Biopharma Dive
Mon, 08/19/19 - 11:48 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
complete response letter
Vyondys 53
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »